Última actualización :
19/11/2024
fármacos contra el cáncer   Epirubicin hydrochloride  
Inyectables
Estabilidad en solucion Estabilidad en mezcla Factores que influyen sobre la estabilidad Compatibilidades método de inyección Bibliografía pdf
   Estructura química  

Nombre comercial   Nombre comercial     

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Anthracine Malasia
Axirubicine Alemania
Bendaepi Alemania
Binarin México
Bioepycina Polonia
Crisabon Argentina
Cuatroepi Argentina
Ecclepia Rumania
Elebicin México
Ellence Estados Unidos de América
Epi Cell Alemania
Epidoxo Argentina, Chile, Venezuela
Epifil Ecuador
Epilem Colombia, México
Epimedac Alemania
Epirubicin Arabia Saudita, Australia, Austria, Bélgica, Dinamarca, Gran Bretaña, Hungría, Islandia, Nueva Zelanda, Suecia, Suiza, Turquía
Epirubicina Argentina, Colombia, Ecuador, España, México, Rumania
Epirubicine Bélgica, Francia, Suiza
Farmarubicin Turquía
Farmorubicin Arabia Saudita, Austria, Brasil, Dinamarca, Finlandia, Grecia, Noruega, Suecia, Suiza
Farmorubicin CSV Sudafrica
Farmorubicin PFS Croacia, Eslovenia, Polonia
Farmorubicin RD Brasil, Polonia, ruso, Suiza
Farmorubicin RTU Países Bajos
Farmorubicina Brasil, España, Italia, Portugal
Farmorubicine Bélgica, Francia
Pharmorubicin Gran Bretaña
Bibliografía   Inyectables   Bibliografía : Epirubicin hydrochloride  
Tipo Publicación
148 periódico Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I.
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525 periódico De Vroe C, De Muynck C, Remon JP, Samsom M.
A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters.
Int J Pharm 1990 ; 65: 49-56.
683 periódico Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C.
Epirubicin stability in syringes and glass vials and evaluation of chemical contamination.
Can J Hosp Pharm 1990 ; 43: 265-272.
686 periódico Wood MJ, Irwin WJ, Scott DK.
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags.
J Clin Pharm Ther 1990 ; 15: 279-289.
887 periódico Pujol M, Munoz M, Prat J, Giona V, De Bolos J.
Stability study of epirubicin in NaCl 0.9% injection.
Ann Pharmacotherapy 1997 ; 31: 992-995.
1237 periódico Keusters L, Stolk LML, Umans R, Van Asten P.
Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation.
Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265 periódico Wood MJ, Irwin WJ, Scott DK.
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography.
J Clin Pharm Ther 1990 ; 15: 291-300.
1317 periódico Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG.
Pharmaceutical aspects of home infusion therapy for cancer patients.
Pharm J 1987 ; 238: 476-478.
1662 periódico Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1823 periódico Sewell GJ, Rigby-Jones AE, Priston MJ.
Stability of intravesical epirubicin infusion: a sequential temperature study.
J Clin Pharm Ther 2003 ; 28: 349-353.
1897 periódico Sautou-Miranda V, Brigas F, Thibault M, Chopineau J.
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage.
EJHP 2001 ; 7, 3: 108-115.
1955 periódico Trissel LA, Zhang Y.
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Ann Pharmacotherapy 2005 ; 39: 280-283.
2168 periódico Ozdemir FA, Anilanmert B, Pekin M.
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257 Laboratorio Stability of epirubicin "Ebewe" infusion solutions.
Ebewe Pharma 2007
3473 periódico Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B.
Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization.
Int J Pharm 2015 ; 495, 2: 956-962.
3474 Laboratorio Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3632 Laboratorio Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics
Hospira 2017
3670 periódico Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3708 póster Sarakbi I, Thiesen J, Krämer I.
Compatibility of epirubicin-loaded DC Beads with different contrast media.
ECOP 2 Krakow 2014
3918 periódico Sarakbi I, Krämer I.
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media.
J Oncol Pharm Practice 2016 ; 22: 749-756.
4352 periódico Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y.
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
J Clin Pharm Ther 2019 ; 44: 875-882.

  Mentions Légales